Probiotica - melkzuurbacteriën (Lactobacillus- en Bifidobacteria) verbeteren significant de aanpak en vernietiging van de Helicobactor Pylori en de infecties daardoor van 85% tot 90%, zelfs bij patienten die resistent waren voor antibiotica. Hier drie ge

25 april 2006: Bronnen: Am J Clin Nutr. 2006 Apr;83(4):864-9. en 1: Am J Clin Nutr. 2004 Sep;80(3):737-41 en 1: Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72

Indien yoghurt met probiotica (met Lactobacillus- en Bifidobacteria) wordt gegeven vooraf en tijdens een behandeling van hardnekkige Helicobacter pylori infecties zijn de resultaten significant beter en wordt de Helicobacter Pylori, de bacterie die vaak verantwoordelijk is voor het ontstaan van darmkanker en maagkanker voor 85% tot 90% gedood. Een meer dan uitstekend resultaat lijkt ons. Zie hieronder drie gerandomiseerde studies die alle met dezelfde resultaten als bewijs komen.

Am J Clin Nutr. 2006 Apr;83(4):864-9

Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy.

Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, Wu JJ. Departments of Internal Medicine, Medical College, National Cheng Kung University, Tainan, Taiwan.

BACKGROUND: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress Helicobacter pylori. Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed.

OBJECTIVE: We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy in eradicating residual H. pylori after failed triple therapy.

DESIGN: One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance. These patients were then randomly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group. The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt (400 mL/d). In the yogurt-plus-quadruple group, excessive delta(13)CO(2)/mL values of the (13)C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt. For both groups, a (13)C-urea breath test was conducted >/=6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication.

RESULTS: For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori, the excessive delta(13)CO(2)/mL values of the (13)C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt (P < 0.0001). The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group (intention-to-treat analysis: 85% compared with 71.1%, P < 0.05; per-protocol analysis: 90.8% compared with 76.6%, P < 0.05).

CONCLUSION: A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance, thus improving the efficacy of quadruple therapy in eradicating residual H. pylori.

PMID: 16600940 [PubMed - in process]

1: Am J Clin Nutr. 2004 Sep;80(3):737-41.

Comment in:
Am J Clin Nutr. 2005 Apr;81(4):939; aithor reply 939-40.

Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori.

Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, Jan CM, Lai CH, Wang TN, Wang WM. Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan, Republic of China.

BACKGROUND: Evidence suggests that ingesting lactic acid bacteria exerts a suppressive effect on Helicobacter pylori infection in both animals and humans. Supplementing with Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) was shown to improve the rates of eradication of H. pylori in humans.

OBJECTIVE: We administered AB-yogurt to subjects with asymptomatic H. pylori to test whether the yogurt could inhibit H. pylori growth.

DESIGN: The in vitro inhibition of H. pylori growth was determined by inoculating Lactobacillus acidophilus La5 or Bifidobacterium lactis Bb12 on plates that were inoculated with H. pylori. Assessment of the viability of H. pylori was performed by the mixed culture method with La5 or Bb12. In an intervention study, 59 adult volunteers infected with H. pylori were given AB-yogurt (10(7) colony-forming units of both La5 and Bb12/mL) twice daily after a meal for 6 wk. Eleven subjects positive for H. pylori infection were treated with milk placebo as control subjects. H. pylori bacterial loads were determined with use of the (13)C-urea breath test, which was performed before and 4 and 8 wk after the start of AB-yogurt supplementation.

RESULTS: Bb12 exerted an in vitro inhibitory effect against H. pylori, whereas La5 did not show an effect. Administration of AB-yogurt decreased the urease activity of H. pylori after 6 wk of therapy (P < 0.0001). CONCLUSION: Regular intake of yogurt containing Bb12 and La5 effectively suppressed H. pylori infection in humans.

Publication Types:
Clinical Trial
Randomized Controlled Trial

PMID: 15321816 [PubMed - indexed for MEDLINE]

1: Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72.

Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study.

Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland.

BACKGROUND: H. pylori is the major cause of chronic gastritis, and a risk factor for peptic ulcer and gastric cancer. AIM: To investigate the effect of probiotic supplementation on the tolerance and efficacy of H. pylori eradication treatment in a randomized, double-blind, placebo-controlled trial.

METHODS: A total of 338 volunteers were screened for H. pylori infection. The eligibility criteria were met by 47 subjects whose H. pylori infection was verified at the outset and re-evaluated after the treatment by the 13C-urea breath test and by enzyme immunoassay serology. The subjects were randomized to receive probiotic therapy (Lactobacillus rhamnosus GG, L. rhamnosusLC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii ssp. shermanii JS) or a placebo during H. pylori eradication and for 3 weeks following the treatment, and recorded their daily symptoms in a standardized diary.

RESULTS: When the frequencies of new or aggravated symptoms were evaluated, no significant differences were found between the two groups for individual symptoms. However, the probiotic group showed less treatment-related symptoms as measured by the total symptom score change (P = 0.038) throughout the H. pylori eradication therapy in contrast to the placebo group. The H. pylori eradication rate was non-significantly higher in the group receiving probiotic therapy (91% vs. 79%, P = 0.42). In this group the recovery of probiotic bacteria in the faeces increased significantly (P < 0.001). CONCLUSIONS: In this pilot study, probiotic supplementation did not diminish significantly the frequency of new or aggravated symptoms during H. pylori eradication. However, our data suggest an improved tolerance to the eradication treatment when total symptom severity was taken into account. Furthermore, the results show that probiotic bacteria are able to survive in the gastrointestinal tract despite the intensive antimicrobial therapy.

Publication Types:
Clinical Trial
Randomized Controlled Trial

PMID: 15882248 [PubMed - indexed for MEDLINE]

Plaats een reactie ...

Reageer op "Probiotica - melkzuurbacteriën (Lactobacillus- en Bifidobacteria) verbeteren significant de aanpak en vernietiging van de Helicobactor Pylori en de infecties daardoor van 85% tot 90%, zelfs bij patienten die resistent waren voor antibiotica. Hier drie ge"

Gerelateerde artikelen